ISU ABXIS Co., Ltd. is a joint venture between ISU Chemical and one of top three medical centers in Korea. Established in 2001, ISU ABXIS has developed and marketed innovative technologies and services to solve unmet medical needs. Backed by the resources and medical expertise, our business focuses primarily on developing technologies for genetic test, anticancer drug screening and the tools for validation of many candidates. We provide one of the best solutions for validating the candidates or for the process of antibody development, and provide automated DNA sequencing & fragment analysis, and develop anticancer drug screening technologies for clinicians and individual patient. In addition, we are developing biomarkers to diagnose a number of other specific diseases and new drug targets using antibody display technology and proteomics, in partnership with a prominent research institutionin Korea and abroad.